Remission in a Patient with Menetrier??s Disease: Spontaneous or Induced by Treatment?

Krol, Thomas C.; Isenberg, Jon I.

doi:10.1097/00004836-198504000-00010

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both cases had lit tle response to H2 blockade, but showed marked subjective and objective improve ment timed exactly with the introduction of omeprazole. Only rare spontaneous recover ies have been reported in the adult form of the disease [11], so it is reasonable to attribute these improvements to the action of omepra zole. Although case numbers limit compre hensive studies, trials on the use of omepra zole in Menetrier's disease are needed.…”

Section: Discussionmentioning

confidence: 99%

Medical Therapy of Ménétrier’s Disease with Omeprazole

Bradburn¹,

Redwood

Venables

et al. 1992

Digestion

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Medical Therapy of Ménétrier’s Disease with Omeprazole

Bradburn¹,

Redwood

Venables

et al. 1992

Digestion

View full text Add to dashboard Cite

show abstract

“…It is regarded as a chronic disease in adults, and only a few cases of spontaneous regression have been reported (3,4). In childhood, on the other hand, Menetrier's disease has been described as pursuing a benign course, and an association with CMV infection has been documented (5,6).…”

Section: Discussionmentioning

confidence: 99%

Giant Hypertrophic Gastritis and Acute Hepatitis Associated with Cytomegalovirus Infection.

Nakazato¹,

Toyoizumi²,

Kinoshita³

et al. 1992

Intern. Med.

View full text Add to dashboard Cite

A 38-year-old man developed prominent hypoproteinemia after acute elevation of serum transaminase levels. Giant hypertrophy of the gastric mucosa, a short serum albumin half-life, and the absence of massive hepatocyte necrosis established the diagnosis of protein-losing gastropathy. The hypoproteinemia, gastric fold hypertrophy and hepatitis remitted sponta neously within 4 months. A high antibody titer against cytomegalovirus suggested an association between the viral infection and the patient's disease. (Internal Medicine 31: 816-819, 1992)

show abstract

“…• [63,64] and proton pump inhibitors [65][66][67] also has met with frequent (though not uniform) success in the literature. Given the benignity of these medications, they are certainly worth an empiric trial, particularly if erosions or ulcers are present.…”

Section: Surgerymentioning

confidence: 99%

Protein-losing enteropathy and gastropathy

Landzberg

Pochapin

2001

Curr Treat Options Gastro

View full text Add to dashboard Cite

The diagnosis of protein-losing enteropathy (PLE) should be considered in all patients with hypoalbuminemia and edema without other known causes, and established by plasma alpha(1)-antitrypsin (alpha(1)-AT) clearance or nuclear studies. The therapy for PLE should focus principally on the treatment of the underlying disease after it has been identified. Therapeutic goals should include improvement of hypoalbuminemia, edema, and lymphopenia. The existing primary literature for therapy of PLE syndromes consists mainly of case reports and expert opinions, subject to substantial reporting bias and unknown rates of spontaneous remission; the rarity of and the diversity among this set of diseases make future large randomized trials unlikely. Therapeutic choices, therefore, must involve clinical acumen, empiricism, and understanding of the pathophysiology of the underlying disease process, and must be tailored to each individual patient's syndrome. Dietary interventions including hypolipidic, high-protein regimens, supplemented by medium-chain triglycerides (MCTs), are extremely useful, particularly in protein loss due to increased lymphatic pressure. Corticosteroids can be very useful in certain cases of PLE (though not without substantial long-term toxicity) when clinical serologic or histologic markers of inflammatory disease are present. Octreotide is a well tolerated drug that has been demonstrated to improve PLE in some patients, and is worth consideration. Octreotide is a well tolerated drug that has been demonstrated to improve PLE in some patients, and is worth consideration. Surgery finds its best role in treating gastrointestinal protein loss from neoplasia, inflammatory bowel disease, and hypertrophic gastritis. Most other PLEs are distributed too widely for surgical intervention. Protein-losing gastropathy (PLG) behaves somewhat differently from the general group of PLE, marked by excellent responses to elimination of Helicobacter pylori, antisecretory therapy, and surgical resection. Protein-losing enteropathy stemming from cardiovascular disease is best treated by medical or surgical cardiovascular interventions; however, some patients may respond to mucosa-directed therapy.

show abstract

Remission in a Patient with Menetrier??s Disease: Spontaneous or Induced by Treatment?

Cited by 9 publications

References 0 publications

Medical Therapy of Ménétrier’s Disease with Omeprazole

Medical Therapy of Ménétrier’s Disease with Omeprazole

Giant Hypertrophic Gastritis and Acute Hepatitis Associated with Cytomegalovirus Infection.

Protein-losing enteropathy and gastropathy

Contact Info

Product

Resources

About